Avacta Expands its Pipeline with Two Novel Assets Developed Using its pre|CISION® Platform
17 10월 2024 - 8:00PM
Avacta Group plc
("Avacta" or "the Group" or "the
Company")Avacta Expands its Pipeline with Two Novel Assets
Developed Using its pre|CISION®
Platform
London, Oct. 17, 2024 – Avacta Group plc (AIM:
AVCT), a life sciences company developing innovative
targeted oncology drugs, today announces the addition of two novel
preclinical oncology assets, AVA6103 and AVA7100, to its pipeline
of pre|CISION®-enabled drug conjugates.
Avacta is developing a portfolio of pre|CISION® product
candidates that are designed to be activated specifically in the
tumor microenvironment, thereby enabling improved antitumor
activity while reducing systemic toxicities. The Company has
developed a pipeline of peptide drug conjugates, each of which is
comprised of an active antitumor drug (known as a payload) linked
to the pre|CISION® peptide, which is cleaved only
within the tumor by the action of Fibroblast Activation Protein, or
FAP.
The first of the two new programs is AVA6103, a novel
pre|CISION®-enabled peptide drug conjugate comprised of the
pre|CISION® peptide linked to exatecan, the most
potent topoisomerase I inhibitor in clinical development. This PDC
is designed to deliver the exatecan payload directly to tumors
while limiting the exposure of the released payload in normal
tissues. Exatecan has demonstrated clinical activity in breast,
gastric, lung and pancreatic cancers; however, it is associated
with severe dose-limiting toxicities and a short half-life in
patients that led to discontinuation of its monotherapy
development. More recently, this payload has been adapted for use
in antibody drug conjugates and other approaches. AVA6103 is
designed to enable patients to obtain the therapeutic benefit
associated with exatecan, while limiting the systemic exposure
associated with its poor tolerability.
The second program is AVA7100, a pre|CISION®-enabled Affimer®
drug conjugate, a new class of therapies being developed by Avacta
with potential applications in a variety of cancer types, including
those with lower levels of FAP in the tumor. Affimer® molecules are
small proteins that are engineered to bind to a target molecule in
the same way that an antibody does, but with several advantages,
including smaller molecule size and greater binding affinity.
AVA7100 consists of a novel FAP-Affimer conjugated to a
pre|CISION-peptide linker with multiple options for the
payload.
Christina Coughlin, MD, PhD,
Chief Executive Officer of Avacta, commented: “The
expansion of our pipeline highlights the broad potential of our
proprietary pre|CISION® technology to deliver multiple potent
oncology therapeutics directly into difficult-to-treat tumors,
while sparing healthy tissues. These novel assets have been
carefully selected to complement our existing portfolio, by
targeting cancers with high unmet need and having clear development
strategies. We look forward to sharing data across our programs in
the near future.”
Further details of these programs will be released in
conjunction with the Company’s two presentations at the
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer
Therapeutics being held in Barcelona from October 23-25, 2024. The
platform and the pipeline will be presented at the investor and
analyst R&D Spotlight Event: Focus on pre|CISION®, in London on
October 30, 2024.
For further information from
Avacta Group plc, please contact:
| Avacta Group
plcMichael Vinegrad, Group Communications
Director |
https://avacta.com |
| Peel Hunt (Nomad and
Broker)James Steel / Chris Golden / Patrick
Birkholm |
www.peelhunt.com |
| ICR Consilium
Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji |
avacta@consilium-comms.com |
About the pre|CISION®
Platform
The pre|CISION® platform comprises an anticancer payload
conjugated to a proprietary peptide that is a highly specific
substrate for fibroblast activation protein (FAP) which is
upregulated in most solid tumors compared with healthy tissues. The
pre|CISION® platform harnesses this tumor specific protease to
cleave pre|CISION® peptide drug conjugates and pre|CISION®
antibody/Affimer® drug conjugates in the tumor
microenvironment, thus releasing active payload in the tumor and
reducing systemic exposure and toxicity, allowing dosing to be
optimized to deliver the best outcomes for patients.
About AVA6000
The lead pre|CISION® program AVA6000, a peptide drug conjugate
form of doxorubicin, is in Phase 1 studies. It has shown an
improvement in safety and tolerability in clinical trials to date
compared with standard doxorubicin and preliminary signs of
clinical activity in multiple patients.To register for news alerts
by email go
to https://avacta.com/investors/investor-news-email-alerts/
About Avacta Group plc:
https://avacta.com/ Avacta Group is
a UK-based life sciences company focused on improving
healthcare outcomes through targeted cancer treatments and
diagnostics. Its clinical stage oncology biotech division Avacta
Therapeutics is harnessing the proprietary pre|CISION® platform
technology to develop novel, highly targeted cancer drugs. Avacta
Diagnostics focuses on supporting healthcare professionals and
broadening access to diagnostics. To register for news alerts by
email go
to https://avacta.com/investors/investor-news-email-alerts/
Avacta (LSE:AVCT)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Avacta (LSE:AVCT)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
